American Century Companies Inc. Boosts Holdings in Halozyme Therapeutics, Inc. $HALO

Key Points

• American Century Companies Inc. increased its stake in Halozyme Therapeutics by 3.4%, owning approximately 895,412 shares valued at $57.14 million as of the latest SEC filing.
• CEO Helen Torley sold 20,000 shares of Halozyme stock for $1.27 million, reducing her total ownership by 2.65% to 733,719 shares.
• Halozyme Therapeutics reported earnings of $1.54 per share for the last quarter, surpassing estimates, with a revenue of $325.72 million - a 40.8% year-over-year increase.

American Century Companies Inc. lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 895,412 shares of the biopharmaceutical company's stock after acquiring an additional 29,046 shares during the period. American Century Companies Inc. owned 0.73% of Halozyme Therapeutics worth $57,136,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Penserra Capital Management LLC purchased a new position in Halozyme Therapeutics in the first quarter valued at approximately $125,000. Bessemer Group Inc. grew its position in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the last quarter. D. E. Shaw & Co. Inc. raised its stake in Halozyme Therapeutics by 171.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after acquiring an additional 524,802 shares in the last quarter. Fifth Third Bancorp raised its stake in Halozyme Therapeutics by 29.4% during the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock worth $639,000 after acquiring an additional 2,276 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Halozyme Therapeutics by 199.0% in the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after acquiring an additional 1,865 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $46,598,493.69. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 80,000 shares of company stock worth $4,532,600 over the last ninety days. Insiders own 2.90% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Morgan Stanley raised their price target on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. JMP Securities lifted their price target on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. HC Wainwright increased their price objective on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $67.11.

Halozyme Therapeutics Price Performance

HALO stock traded up $0.39 on Monday, reaching $72.21. 1,644,894 shares of the company's stock were exchanged, compared to its average volume of 2,149,365. The stock has a fifty day moving average of $59.09 and a 200-day moving average of $58.86. The firm has a market cap of $8.45 billion, a PE ratio of 16.52, a P/E/G ratio of 0.41 and a beta of 1.17. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $73.47.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same period in the previous year, the firm earned $0.91 EPS. The business's revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.